ProQR Q2 revenue and EPS miss estimates

Reuters

2025/08/07

ProQR <a href="https://laohu8.com/S/QTWO">Q2</a> revenue and EPS miss estimates

Overview

ProQR Q2 revenue and EPS miss analysts' expectations, per LSEG data
Co submitted CTA for AX-0810, targeting NTCP for cholestatic diseases
ProQR holds EUR119.8 mln cash, providing runway into mid-2027

Outlook

ProQR expects initial AX-0810 Phase 1 data in Q4 2025
Company anticipates AX-2402 clinical candidate selection in 2025
ProQR's cash runway extends into mid-2027, excluding Lilly milestones

Result Drivers

LILLY PARTNERSHIP - Achieved milestones in collaboration with Eli Lilly, contributing €1.8 mln to revenue

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue	Miss	EUR 3.82 mln	EUR 4.45 mln (7 Analysts)
Q2 EPS	Miss	-EUR 0.12	-EUR 0.08 (7 Analysts)
Q2 Net Income	Miss	-EUR 12.18 mln	-EUR 8.99 mln (6 Analysts)
Q2 Operating Income	Miss	-EUR 12.25 mln	-EUR 8.77 mln (5 Analysts)
Q2 Basic EPS		-EUR 0.12

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for ProQR Therapeutics NV is $9.00, about 77.1% above its August 6 closing price of $2.06

Press Release: ID:nGNE8yKjqm

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557557846"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557557846\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557557846?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557557846","market":"us","top_or_hot":-1,"title":"ProQR Q2 revenue and EPS miss estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ProQR <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue and EPS miss estimates</title></head><body><p><span>Overview</span></p><ul><li><p>ProQR Q2 revenue and EPS miss analysts' expectations, per LSEG data</p></li><li><p>Co submitted CTA for AX-0810, targeting NTCP for cholestatic diseases</p></li><li><p>ProQR holds EUR119.8 mln cash, providing runway into mid-2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>ProQR expects initial AX-0810 Phase 1 data in Q4 2025</p></li><li><p>Company anticipates AX-2402 clinical candidate selection in 2025</p></li><li><p>ProQR's cash runway extends into mid-2027, excluding Lilly milestones</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LILLY PARTNERSHIP - Achieved milestones in collaboration with Eli Lilly, contributing €1.8 mln to revenue</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Miss</p></td><td><p>EUR 3.82 mln</p></td><td><p>EUR 4.45 mln (7 Analysts)</p></td></tr><tr><td><p>Q2 EPS</p></td><td><p>Miss</p></td><td><p>-EUR 0.12</p></td><td><p>-EUR 0.08 (7 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Miss</p></td><td><p>-EUR 12.18 mln</p></td><td><p>-EUR 8.99 mln (6 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Miss</p></td><td><p>-EUR 12.25 mln</p></td><td><p>-EUR 8.77 mln (5 Analysts)</p></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-EUR 0.12</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for ProQR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> NV is $9.00, about 77.1% above its August 6 closing price of $2.06</p></li></ul><p>Press Release: <span>ID:nGNE8yKjqm</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ProQR Q2 revenue and EPS miss estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProQR Q2 revenue and EPS miss estimates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-07 19:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ProQR <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue and EPS miss estimates</title></head><body><p><span>Overview</span></p><ul><li><p>ProQR Q2 revenue and EPS miss analysts' expectations, per LSEG data</p></li><li><p>Co submitted CTA for AX-0810, targeting NTCP for cholestatic diseases</p></li><li><p>ProQR holds EUR119.8 mln cash, providing runway into mid-2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>ProQR expects initial AX-0810 Phase 1 data in Q4 2025</p></li><li><p>Company anticipates AX-2402 clinical candidate selection in 2025</p></li><li><p>ProQR's cash runway extends into mid-2027, excluding Lilly milestones</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LILLY PARTNERSHIP - Achieved milestones in collaboration with Eli Lilly, contributing €1.8 mln to revenue</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Miss</p></td><td><p>EUR 3.82 mln</p></td><td><p>EUR 4.45 mln (7 Analysts)</p></td></tr><tr><td><p>Q2 EPS</p></td><td><p>Miss</p></td><td><p>-EUR 0.12</p></td><td><p>-EUR 0.08 (7 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Miss</p></td><td><p>-EUR 12.18 mln</p></td><td><p>-EUR 8.99 mln (6 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Miss</p></td><td><p>-EUR 12.25 mln</p></td><td><p>-EUR 8.77 mln (5 Analysts)</p></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-EUR 0.12</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for ProQR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> NV is $9.00, about 77.1% above its August 6 closing price of $2.06</p></li></ul><p>Press Release: <span>ID:nGNE8yKjqm</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRQR","symbol_name":"ProQR Therapeutics N.V.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLX950AE4:1","article_id":"2557557846","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557557846","pubTimestamp":1754564895,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ProQR Q2 revenue and EPS miss estimatesOverviewProQR Q2 revenue and EPS miss analysts' expectations, per LSEG dataCo submitted CTA for AX-0810, targeting NTCP for cholestatic diseasesProQR holds EUR11","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PRQR":"ProQR Therapeutics N.V."},"translate_title":"ProQR第二季度收入和每股收益未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRQR":0.9},"content_text":"ProQR Q2 revenue and EPS miss estimatesOverviewProQR Q2 revenue and EPS miss analysts' expectations, per LSEG dataCo submitted CTA for AX-0810, targeting NTCP for cholestatic diseasesProQR holds EUR119.8 mln cash, providing runway into mid-2027OutlookProQR expects initial AX-0810 Phase 1 data in Q4 2025Company anticipates AX-2402 clinical candidate selection in 2025ProQR's cash runway extends into mid-2027, excluding Lilly milestonesResult DriversLILLY PARTNERSHIP - Achieved milestones in collaboration with Eli Lilly, contributing €1.8 mln to revenueKey DetailsMetricBeat/MissActualConsensus EstimateQ2 RevenueMissEUR 3.82 mlnEUR 4.45 mln (7 Analysts)Q2 EPSMiss-EUR 0.12-EUR 0.08 (7 Analysts)Q2 Net IncomeMiss-EUR 12.18 mln-EUR 8.99 mln (6 Analysts)Q2 Operating IncomeMiss-EUR 12.25 mln-EUR 8.77 mln (5 Analysts)Q2 Basic EPS-EUR 0.12Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for ProQR Therapeutics NV is $9.00, about 77.1% above its August 6 closing price of $2.06Press Release: ID:nGNE8yKjqm(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}